Northern Trust Corp Rocket Pharmaceuticals, Inc. Transaction History

Northern Trust Corp

$690 Billion
Q4 2024

A detailed history of Northern Trust Corp transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 663,152 shares of RCKT stock, worth $6.94 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

663,152

Previous 580,836 14.17%

Holding current value

$6.94 Million

Previous $10.7 Million 22.31%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$11.35 - $18.82 $934,286 - $1.55 Million	82,316 Added 14.17%	663,152 $8.34 Million
Q3 2024 Nov 13, 2024	SELL	$17.6 - $25.88 $136,593 - $200,854	-7,761 Reduced 1.32%	580,836 $10.7 Million
Q2 2024 Aug 14, 2024	SELL	$20.66 - $26.72 $442,950 - $572,876	-21,440 Reduced 3.51%	588,597 $12.7 Million
Q1 2024 May 14, 2024	SELL	$26.16 - $30.74 $488,354 - $573,854	-18,668 Reduced 2.97%	610,037 $16.4 Million
Q4 2023 Feb 13, 2024	BUY	$16.78 - $31.94 $768,691 - $1.46 Million	45,810 Added 7.86%	628,705 $18.8 Million
Q3 2023 Nov 13, 2023	BUY	$15.07 - $24.05 $137,091 - $218,782	9,097 Added 1.59%	582,895 $11.9 Million
Q2 2023 Aug 11, 2023	BUY	$16.59 - $23.6 $442,820 - $629,931	26,692 Added 4.88%	573,798 $11.4 Million
Q1 2023 May 15, 2023	BUY	$15.79 - $22.6 $91,629 - $131,147	5,803 Added 1.07%	547,106 $9.37 Million
Q4 2022 Feb 13, 2023	BUY	$15.5 - $22.76 $1.75 Million - $2.56 Million	112,618 Added 26.27%	541,303 $10.6 Million
Q3 2022 Nov 14, 2022	SELL	$12.37 - $18.41 $31,691 - $47,166	-2,562 Reduced 0.59%	428,685 $6.84 Million
Q2 2022 Aug 12, 2022	BUY	$7.96 - $16.64 $165,496 - $345,962	20,791 Added 5.07%	431,247 $5.93 Million
Q1 2022 May 13, 2022	SELL	$13.16 - $23.68 $21,371 - $38,456	-1,624 Reduced 0.39%	410,456 $6.51 Million
Q4 2021 Feb 08, 2022	SELL	$21.52 - $36.02 $54,617 - $91,418	-2,538 Reduced 0.61%	412,080 $9 Million
Q3 2021 Nov 15, 2021	SELL	$27.42 - $48.97 $383,496 - $684,894	-13,986 Reduced 3.26%	414,618 $12.4 Million
Q2 2021 Aug 13, 2021	BUY	$39.41 - $47.25 $155,827 - $186,826	3,954 Added 0.93%	428,604 $19 Million
Q1 2021 May 12, 2021	BUY	$43.34 - $65.91 $643,295 - $978,302	14,843 Added 3.62%	424,650 $18.8 Million
Q4 2020 Feb 11, 2021	SELL	$23.3 - $59.57 $50,980 - $130,339	-2,188 Reduced 0.53%	409,807 $22.5 Million
Q3 2020 Nov 16, 2020	SELL	$20.5 - $28.59 $454,095 - $633,297	-22,151 Reduced 5.1%	411,995 $9.42 Million
Q2 2020 Aug 14, 2020	BUY	$13.32 - $22.61 $307,225 - $521,499	23,065 Added 5.61%	434,146 $9.09 Million
Q1 2020 May 14, 2020	BUY	$9.71 - $25.11 $515,999 - $1.33 Million	53,141 Added 14.85%	411,081 $5.74 Million
Q4 2019 Feb 14, 2020	SELL	$11.07 - $24.23 $130,581 - $285,817	-11,796 Reduced 3.19%	357,940 $8.15 Million
Q3 2019 Nov 13, 2019	BUY	$10.85 - $14.78 $666,862 - $908,408	61,462 Added 19.94%	369,736 $4.31 Million
Q2 2019 Aug 13, 2019	BUY	$15.0 - $19.81 $41,760 - $55,151	2,784 Added 0.91%	308,274 $4.62 Million
Q1 2019 May 13, 2019	BUY	$13.45 - $19.01 $244,386 - $345,411	18,170 Added 6.32%	305,490 $5.36 Million
Q4 2018 Feb 12, 2019	BUY	$11.21 - $23.53 $162,208 - $340,479	14,470 Added 5.3%	287,320 $4.26 Million
Q3 2018 Nov 14, 2018	BUY	$18.5 - $25.49 $625,559 - $861,918	33,814 Added 14.15%	272,850 $6.72 Million
Q2 2018 Sep 18, 2018	BUY	$14.58 - $23.0 $222,199 - $350,520	15,240 Added 6.81%	239,036 $4.69 Million
Q2 2018 Aug 14, 2018	BUY	$14.58 - $23.0 $2.78 Million - $4.39 Million	190,698 Added 576.16%	223,796 $4.39 Million
Q1 2018 May 09, 2018	BUY	$11.68 - $19.19 $386,584 - $635,150	33,098 New	33,098 $620,000

Others Institutions Holding RCKT

# of Institutions

244

Shares Held

108M

Call Options Held

262K

Put Options Held

159K

View Full List

About ROCKET PHARMACEUTICALS, INC.

Ticker RCKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 75,683,696
Market Cap $792M
Description
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...

More about RCKT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Rocket Pharmaceuticals, Inc. Transaction History